North East and North Cumbria
ICS Formulary
ICS Formulary
9 Nutrition and blood
09-01-03 Iron overload
Links
NICE TA647: Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)
Clinical Commissioning Policy: Eculizumab in the treatment of recurrence of C3 glomerulopathy postkidney transplant (all ages) Reference: NHS England: 16054/P- County Durham and Tees Valley Guidelines for recognition and management of non- IgE cow’s milk allergy in children
- Guidance for the Prescribing of Vitamins and Minerals in Primary Care in County Durham and Tees Valley
- MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
- MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
- MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
- MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
- MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
- NICE CG114: Anaemia in chronic kidney disease
- NICE HST 1 - Eculizumab for treating atypical haemolytic uraemic syndrome
- NICE NG203: Chronic kidney disease: assessment and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
- NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
- NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
- NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
- NICE TA636: Eculizumab for treating refractory myasthenia gravis (terminated appraisal)
- NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
- NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
- NICE TA778: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria
- NICE TA807: Roxadustat for treating symptomatic anaemia in chronic kidney disease
- North of Tyne, Gateshead and North Cumbria - Guidelines for detection, management and referral of adults with kidney disease
- North of Tyne, Gateshead and North Cumbria - Recommendations for symptom management in renal patients (including symptom management at the end of life)
- North of Tyne, Gateshead and North Cumbria - Shared Care Guidelines for the Monitoring of Erythropoietins in the Treatment of Patients with Chronic Kidney Disease (CKD)
- Shared Care Guidelines for the Monitoring of Erythropoietins in the Treatment of Patients with Chronic Kidney Disease (CKD)
- Shared Care Guidelines for the Monitoring of Erythropoietins in the Treatment of Patients with Chronic Kidney Disease (CKD)
- South Tees Pathway for the Management of Undernutrition (ADULTS)
- South Tees Pathway for the Management of Undernutrition (Nursing/Care Homes)